-
The research finds that the medicine, called Paxlovid, was effective in preventing hospitalization and death when taken by people with mild to moderate illness within a few days of symptoms.
-
Pfizer researchers looking for a drug to treat SARS found clues that gave the company a head start in its quest for a pill to treat COVID-19, including the omicron variant.
-
The companies say a study of more than 10,000 volunteers showed a vaccine efficacy of 95% or greater for people receiving the booster.
-
Based on the strength of the trial's results, Pfizer says it will ask the FDA for emergency use authorization rather than enroll more people for clinical trials.
-
Kids ages 5 to 11 will soon be able to get Pfizer's low-dose COVID vaccine. CDC director Rochelle Walensky agreed with a unanimous decision of a team of advisers that the benefits outweigh the risks.
-
After some debate, a group of scientists advising the FDA concluded that the vaccine's benefits outweigh its risks for young children.
-
The companies studied a 10 microgram vaccine dose in children 5 to 11, a third of the dose used for adults, to minimize side effects and because it still prompts a strong immune response.
-
Should people who get a COVID booster get a different vaccine from their original shot? The results of a highly anticipated study suggest that in some cases the answer may be yes.
-
President Biden said the U.S. will buy 500 million more vaccine doses. The goal is to vaccinate 70% of the world's population within a year. But more rich nations need to pitch in, he said.
-
Pfizer and BioNTech say that early trial results show their vaccine established a strong antibody response against the coronavirus. FDA review is still needed.